Published in Clin Cancer Res on June 01, 2000
Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61
Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol (2015) 0.82
Response rates of patients with metastatic melanoma to high-dose intravenous interleukin-2 after prior exposure to alpha-interferon or low-dose interleukin-2. J Immunother (2002) 0.77
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 10.20
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Purification and some characteristics of human T-cell growth factor from phytohemagglutinin-stimulated lymphocyte-conditioned media. Proc Natl Acad Sci U S A (1980) 4.91
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J Exp Med (1981) 3.30
T-cell lines established from human T-lymphocytic neoplasias by direct response to T-cell growth factor. Proc Natl Acad Sci U S A (1980) 2.89
Lymphokines. N Engl J Med (1987) 2.77
Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood (1997) 2.66
Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. Proc Natl Acad Sci U S A (1982) 2.51
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis. Blood (2001) 2.40
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Multiple biological activities of human recombinant interleukin 1. J Clin Invest (1986) 2.16
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res (1997) 2.08
Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J Biol Chem (2000) 1.97
Calpain regulates actin remodeling during cell spreading. J Cell Biol (1998) 1.90
An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med (1990) 1.89
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med (1988) 1.82
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol (1994) 1.76
Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J Biol Chem (2001) 1.64
Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 1.63
Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer (2013) 1.57
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol (1988) 1.56
Nosocomial sepsis associated with interleukin-2. Ann Intern Med (1990) 1.56
Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease. Blood (2001) 1.52
A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer (2000) 1.52
Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine-activated killer cells. J Clin Oncol (1990) 1.49
Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial. Ann Intern Med (1988) 1.46
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood (2001) 1.46
Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol (1993) 1.45
IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest (1999) 1.44
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med (1993) 1.39
Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response. Clin Cancer Res (2000) 1.38
The purification and properties of human T cell growth factor. J Immunol (1982) 1.24
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res (1999) 1.20
Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol (1989) 1.19
Development and characterization of allospecific long-term human cytolytic T-cell lines. Proc Natl Acad Sci U S A (1980) 1.18
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma. J Clin Oncol (1993) 1.16
The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol (1982) 1.15
Patient preferences for adjuvant interferon alfa-2b treatment. J Clin Oncol (2001) 1.14
Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol (1993) 1.14
Induction of circulating IL-1 receptor antagonist by IFN treatment. J Immunol (1993) 1.13
Studies on mechanisms of augmentation of liver regeneration by cyclosporine and FK 506. Hepatology (1991) 1.13
IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol (1988) 1.08
Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. Cancer Res (1986) 1.08
Long-term remission in a patient with metastatic collecting duct carcinoma treated with taxol/carboplatin and surgery. Urology (2001) 1.07
Interleukins. Annu Rev Med (1986) 1.06
Benchmark testing the Digital Imaging Network-Picture Archiving and Communications System proposal of the Department of Defense. J Digit Imaging (1999) 1.05
Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood (1998) 1.05
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol (2001) 1.04
Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines. Med Oncol (2001) 1.03
Melanotropin receptors demonstrated in situ in human melanoma. J Clin Invest (1990) 0.99
IL-2 rapidly induces natural killer cell adhesion to human endothelial cells. A potential mechanism for endothelial injury. J Immunol (1988) 0.99
Cholecystokinin enhanced hepatobiliary scanning with ejection fraction calculation as an indicator of disease of the gallbladder. Surg Gynecol Obstet (1991) 0.98
Ras- and Raf-induced down-modulation of non-muscle tropomyosin are MEK-independent. J Biol Chem (1998) 0.97
Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol (2012) 0.96
Human T-cell growth factor: parameters for production. J Supramol Struct (1980) 0.96
A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy. J Immunol Methods (1993) 0.95
Nephrectomy before interleukin-2 therapy for patients with metastatic renal cell carcinoma. J Urol (1997) 0.94
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol (1986) 0.93
Leukotriene C4 uses a probenecid-sensitive export carrier that does not recognize leukotriene B4. Proc Natl Acad Sci U S A (1992) 0.93
Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans. Blood (1993) 0.92
Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res (1988) 0.90
Requirement for Shc in TCR-mediated activation of a T cell hybridoma. J Immunol (1999) 0.90
Biosynthesis and post-translational modification of CD6, a T cell signal-transducing molecule. J Biol Chem (1991) 0.90
Economic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol (1997) 0.89
Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases. Cancer Res (1992) 0.88
Symptomatic exacerbation of Crohn disease after treatment with high-dose interleukin-2. Ann Intern Med (1993) 0.86
Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol (1991) 0.85
Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12. J Immunother (2001) 0.85
Regulation of hepatic acute phase protein synthesis by products of interleukin 2 (IL 2)-stimulated human peripheral blood mononuclear cells. J Immunol (1987) 0.84
Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections. J Immunol (2000) 0.84
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin. Dis Colon Rectum (1994) 0.84
Tropomyosin-2 cDNA lacking the 3' untranslated region riboregulator induces growth inhibition of v-Ki-ras-transformed fibroblasts. Mol Biol Cell (1997) 0.83
Clinical use of systemic IL-12 therapy. Cancer Chemother Biol Response Modif (2001) 0.83
Homeless adolescents: a descriptive study of similarities and differences between runaways and throwaways. Adolescence (1985) 0.83
Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol (1997) 0.83
Phase I evaluation of thrice-daily intravenous bolus interleukin-4 in patients with refractory malignancy. J Clin Oncol (1992) 0.82
L-selectin crosslinking induces integrin-dependent adhesion: evidence for a signaling pathway involving PTK but not PKC. Cell Adhes Commun (1996) 0.82
Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunologic effects. J Clin Oncol (1993) 0.82
A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma. J Clin Oncol (1992) 0.82
Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen. J Clin Oncol (1990) 0.81
Granulocyte-macrophage colony stimulating factor potentiates human polymorphonuclear leukocyte aggregation responses to formyl-methionyl-leucyl-phenylalanine. Immunol Lett (1992) 0.81